Michael Grainger is an associate in Goodwin’s Technology and Life Sciences groups in London. Mike advises clients on a broad range of corporate matters, with a focus on transactions in the life sciences, healthcare, and technology sectors. He has particular experience advising on private equity and venture capital investments/exits, mergers and acquisitions, corporate finance, and re-organisations as well as general corporate matters.

Areas of Practice
Domaines D’Expertise






  • M&A Transactions
    • Advising KaNDy Therapeutics on its sale to Bayer for $425 million upfront with up to $450 million in development milestone payments and triple digit millions in commercial milestones.  
    • Advising Enterprise Therapeutics Ltd on the demerger and subsequent acquisition of its TMEM16A potentiator portfolio by Roche for an upfront consideration of £75 million and significant potential milestone payments.
    • Scottish Equity Partners-backed Dotmatics Limited on its sale to Insightful Science, an Insight Partners portfolio company providing software to the global life sciences community.
    • Advising Symprove Holdings Limited and its shareholders, on the sale of 100% of its share capital, to bd-capital for a total initial consideration of approximately £40 million.
    • Arctos Medical AG and its shareholders on the sale of 100% of its share capital to Novartis
    • Ares on the provision of their financing package in support of Midlothian Capital Partners to acquire Park Leisure.*
    • The selling shareholders in Ziarco Group Limited in connection with the sale of the company to Novartis.*
    • Mid Europa Partners on the acquisition of the entire issued share capital of Profi Rom Food S.R.L from Enterprise Investors.*

  • IPO

VC Transactions

  • Investor
    • Advising Y Combinator’s Continuity growth fund as lead investor on a Series F investment of £113 million ($144 million) into Monzo Bank Limited.
    • Advising Lakestar on its series A investments into Yapily Ltd and Uncapped Ltd.
    • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited.
    • Representing the lead investor LSP Health Economics Fund 2 (advised by Life Science Partners) on the $28 million series C equity financing round of Lumeon Limited.
    • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited.
    • InMotion Ventures (part of the Jaguar Land Rover group) — Advised on various transactions including its investments into Arc.

  • Company
    • Vaccitech Limited in its $168 million Series B financing.
    • Advising NodThera Limited on its $55 million Series B equity financing.
    • Advising Exscientia Limited (an AI-driven drug discovery company) on its $26 million series B equity financing round. The Investors were Celgene Corporation, GT Healthcare Capital Partners and Evotec AG.
    • Brytlyt Limited, a company that is developing and commercializing GPU-accelerated data processing technology, on its completion of a £3.2 million Series A funding round led by Amadeus V Technology Fund LP and Finch Capital Fund II Cooperatief U.A.
    • Bicycle Therapeutics Limited on its £40 million Series B equity financing round, led by Vertex Global Fund I alongside Cambridge Innovation Capital and Longwood Fund, with existing investors including Novartis Venture Fund, SR One, and SVLS also participating in the round.*

* Denotes experience prior to joining Goodwin.

In The News









Legal Practice Course, 2015
The University of Law London
GDL, 2014
BPP Law School
B.A., English and Related Literature, 2009
University of York



Solicitor of the Senior Courts of England and Wales
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique